Agios Pharmaceuticals, Q1
AGIO Stock Earnings: Agios Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
AGIO stock results show that Agios Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires.
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call Transcript
May 2, 2024 Agios Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to Agios’ First Quarter 2024 Conference Call.
Agios Pharmaceuticals: Q1 Earnings Snapshot
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Agios Pharmaceuticals Inc. (AGIO) on Thursday reported a loss of $81.5 million in its first quarter. The Cambridge, Massachusetts-based company said it had a loss of $1.45 per share.
Agios Pharmaceuticals Reports Q1 2024 Earnings: Narrower Loss than Expected with Strong Revenue ...
Cash Position: Ended Q1 2024 with $714.3 million in cash, cash equivalents, and marketable securities, down from $806.4 million at the end of 2023. Product Pipeline: Positive Phase 3 results for mitapivat in non-transfusion-dependent thalassemia and upcoming milestones include potential FDA approval filings for thalassemia by year-end.
newsheater8d
Agios Pharmaceuticals Inc (AGIO) Stock: A Closer Look at the Market Potential
In a nutshell, Agios Pharmaceuticals Inc (AGIO) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that ...
Business Insider2d
Agios Reports Business Highlights and First Quarter 2024 Financial Results
May 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today reported business ...
Benzinga.com2y
Agios Pharmaceuticals Stock (NASDAQ:AGIO), Quotes and News Summary
Agios Pharmaceuticals Inc (NASDAQ: AGIO) says the Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary Vandana ...
Morningstar22d
Agios Pharmaceuticals Inc AGIO
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...